- The founder-led business is a profitable, cash flow positive business that is trading at a slight discount now.
- Six quarters after its IPO, the company has demonstrated a strong record of meeting/beating analysts' revenue and earnings estimates.
- The company's greatest asset is the management team with their depth and breadth of industry knowledge.
- The business model of investing into drugs in late-stage clinical trials, already approved therapies, and through M&As bears less risk compared to a traditional pharmaceutical company.
- The company is committed to rewarding their shareholders through dividends that have grown 13% YoY.
For further details see:
Royalty Pharma: A Pharma-Like Company Without The Same Risks